Life Science Investing Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting
Life Science Investing New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting
Seegnal's operating subsidiary Seegnal E-Health Ltd. hires AI VP to Strengthen AI Capabilities and Accelerates Development of Seegnal Guard
